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MOBILE MEDICAL APP REGULATION: 
PREVENTING A PANDEMIC OF “MOBILECHONDRIACS” 
I.  INTRODUCTION 
Good news for number crunchers, bad news for hypochondriacs: the 
human body has been digitized. Advancements in biotechnology and 
human genome sequencing,1 paralleled by the exponential saturation of 
wireless communication networks over the last decade,2 have opened the 
door for software programmers to turn wireless devices like smartphones, 
tablet computers, and personal digital assistants (PDAs) into mobile medical 
devices.3 This confluence of medicine and telecommunications ignites a new 
healthcare paradigm4 in which the human body becomes a mine filled with 
golden patient data, the smartphone becomes a pickaxe, and doctors 
become statistical prospectors who can now diagnose, treat, and soon 
prevent illness anywhere, in real time. And while some who have already 
joined the gold rush find themselves sifting through mountains of new 
medical data, both patient and doctor must tread lightly in transitioning to 
hyper-informed consent and preventative care models5 until the application 
software (app) industry and the federal government begin to work together 
 
 1. Francis S. Collins et al., A Vision for the Future of Genomics Research, 422 NATURE 
835, 835 (2003), available at http://www.nature.com/nature/journal/v422/n6934/pdf/na 
ture01626.pdf. The National Human Genome Research Institute announced the complete 
sequencing of the entire human genome on April 24, 2003. See About NHGRI: A Brief History 
and Timeline, NATIONAL HUMAN GENOME RESEARCH INSTITUTE, http://www.genome.gov/10001 
763 (last visited Nov. 17, 2013) (providing a timeline of the institute’s past and recent efforts). 
 2. ERIC TOPOL, THE CREATIVE DESTRUCTION OF MEDICINE 3-5 (2012). 
 3. See Joshua Brustein, Coming Next: Using an App as Prescribed, N.Y. TIMES, Aug. 20, 
2012, at B1, available at http://www.nytimes.com/2012/08/20/technology/coming-next-doc 
tors-prescribing-apps-to-patients.html; Peter Wayner, Monitoring Your Health with Mobile 
Devices, N.Y. TIMES, Feb. 23, 2013, at B7, available at http://www.nytimes.com/2012/02/ 
23/technology/personaltech/monitoring-your-health-with-mobile-devices.html. 
 4. TOPOL, supra note 2, at 5. See also Charles M. Davids & Michael J. Santorelli, Seizing 
the Mobile Moment: Spectrum Allocation Policy for the Wireless Broadband Century, 19 
COMMLAW CONSPECTUS 1, 19 (2010) (“Broadband [internet access] is . . . enabling a universe 
of telemedicine services that provide a number of life-enhancing, and potentially lifesaving 
benefits.”). 
 5. See Wayner, supra note 3 (suggesting that “[t]here are some really progressive doctors 
who are recognizing the opportunities here for better care and prevention, but most are 
resistant to change”). 
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to ensure that the biodata collected by real live patients is not simply fool’s 
gold.6 
Smartphones are inexpensive, multi-use, portable computing platforms 
whose apps can be installed, updated, and accessed with the simple tap of 
a finger, instantaneously transforming the functionality of the device to 
satisfy every whim of the beholder. As Dr. Eric Topol aptly analogized, these 
adaptable pocket supercomputers are like “pluripotent stem cells, capable 
of acting as our calculator, alarm clock, photo album, watch, camera, 
video and voice recorders, flashlight, and more.”7 Amidst the vast sea of 
high-cost, limited-function medical devices currently occupying care facilities 
nationwide, a physician can consolidate much of her office and laboratory 
into a messenger bag containing only a hand-held smartphone or tablet 
and an array of small attachable accessories.8 In fact, mobile medical apps 
and accessories capable of collecting, translating, and analyzing myriad 
signals from a patient’s body are already on the market.9 Apps can already 
detect low glucose levels,10 regulate high blood pressure,11 prevent 
impending heart attacks,12 and “smell” a patient’s breath for organic 
compounds found in cancerous cells13 — all in real time, all for the sake of 
preventive care. To return to the mining metaphor, the smartphone not only 
serves as a pickaxe for mining data, but also acts as a canary in the coal 
mine,14 alerting patients to the presence of hidden dangers. 
 
 6. Id. (“Some of the attempts to turn the iPhone into a medical device are little more than 
toys.”). See also Jenny Gold, Medical Apps Bump up against Regulators, USA TODAY, July 3, 
2012, at 5D. 
 7. TOPOL, supra note 2, at 62. See also Ian Murnaghan, Pluripotent Stem Cells, EXPLORE 
STEM CELLS, http://www.explorestemcells.co.uk/pluripotentstemcells.html (last visited Feb. 17, 
2013) (finding that in cellular biology, a pluripotent stem cell has the potential to “differentiate 
into almost any cell in the body” prior to its embryonic stage). 
 8. Abraham Verghese, M.D., The Things We Carried, Then and Now, N.Y. TIMES, Oct. 9, 
2012, at D2 (“As technology advances and gets more portable, I see [doctors] bringing more 
tools to the bedside . . . instead of sending [patients] hither and thither to diagnostic suites.”). 
 9. Brian Dolan, Analysis: 75 FDA-cleared Mobile Medical Apps, MOBI HEALTH NEWS, 
(Dec. 12, 2012), http://mobihealthnews.com/19638/analysis-75-fda-cleared-mobile-medi 
cal-apps/.  
 10. See, e.g., Brian Dolan, FDA Clears AgaMatrix’s iPhone Glucose Meter, MOBI HEALTH 
NEWS (Dec. 7, 2011), http://mobihealthnews.com/15137/fda-clears-agamatrixs-iphone-glu 
cose-meter/. 
 11. TOPOL, supra note 2, at 69. 
 12. Id. at 68. 
 13. Id. at 164-65; Katherine Bourzac, Cancer Breath Test Enters Clinical Trials, MIT TECH. 
REVIEW (Feb. 14, 2012), http://www.technologyreview.com/news/426894/cancer-breath-test-
enters-clinical-trials/. 
 14. Long ago, miners brought canary birds or mice into coal mines to detect deadly gases. 
Essentially, if the caged canary died in the mine, the level of carbon monoxide or other gas was 
too high, signaling the need for emergency evacuation of all miners. See Walter H. Page & 
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The influx of mobile medical apps and devices on the horizon could 
likely cause a shift from reaction-based care to prevention-based care. For 
example, a physician treating a patient at risk of diabetes could prescribe an 
app to monitor a patient’s glucose levels15 and another to encourage 
healthy eating and exercise choices.16 Doctors and patients can then employ 
more individualized data to derive a treatment plan that is potentially more 
effective than conventional population-based prescription methods.17 
Treatments beneficial to a number of clinical trial participants often prove 
harmful to a specific subset of patients whose attenuated circumstances, 
comorbidity factors, or genetic aversions to certain drugs complicate 
effective prescribing.18 Wireless monitoring via smartphone could help shift 
the practice of medicine away from a one-size-fits-most19 approach and 
toward a model based on a walking one-person medical trial. Such 
individualized and highly-informed decision-making can improve the overall 
quality of patient care20 and drastically reduce the likelihood of unnecessary 
or ineffective treatments and tests,21 which can result in the additional 
benefit of saving the patient and provider money. All this rests on the 
presumption, however, that these new mobile medical apps and devices 
actually work as intended. 
Ensuring the safety and efficacy of mobile medical apps requires 
regulation that balances consumer safety and freedom to innovate. The 
potential benefits for patients and health care providers are limitless, but so 
 
Arthur W. Page, Resuscitation Cage for Mine Canaries, 28 THE WORLD’S WORK: REDRAWING 
THE RAILROAD MAP OF THE WORLD 474, 474 (1914). 
 15. See, e.g., About iBGStar, iBGSTAR.US, http://www.ibgstar.us/what-is-ibgstar.aspx (last 
visited Jan. 23, 2013). 
 16. See, e.g., Diabetes Nutrition & Diet Tracker by Fooducate, ITUNES APP STORE, 
https://itunes.apple.com/us/app/diabetes-nutrition-diet-tracker/id545282286?mt=8 (last 
visited Feb. 18, 2013). 
 17. See TOPOL, supra note 2, at 210-15 (arguing that constant wireless monitoring 
illuminates nuances in different patients with the same illnesses, which means “massive trials of 
population-based medicine would no longer be needed; instead we could design trials of a 
few hundred patients at most”). 
 18. See id. at 210. 
 19. See id. at 21-22 (describing “large-scale randomized, double-blind, placebo-
controlled clinical trial[s]” as “population medicine, the antithesis of medicine directed at and 
for an individual”). 
 20. See Paul J. Fortier et al., Improved Patient Outcomes through Collaborative Monitoring 
and Management of Subtle Behavioral and Physiological Health Changes, 44 HAW. INT’L 
CONF. SYSTEM SCIS. PROC. 1 (2011), available at http://www.hicss.hawaii.edu/hicss_44/bp44/ 
CL12.pdf. 
 21. Edmond M. Cronin et al., Remote Monitoring of Cardiovascular Devices: A Time and 
Activity Analysis, 9 HEART RHYTHM 1947, 1947-48 (2012). 
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too may be the potential pitfalls.22 A consumer monitoring his own medical 
data may become acutely and intimately aware of confusing or worrisome 
data to the harmful extent that the technology could cause more false 
alarms than anticipated.23 Factors contributing to the end result of an 
undesirable user response could be as foreseeable as design defects and 
software glitches. However, on a more ethereal level, even the way in which 
health data is displayed to the user within the app itself must be carefully 
considered and executed, as even an app’s aesthetics could interfere with its 
effectiveness.24 Further, not all apps are created equal; some health apps 
simply provide information, others may collect and transmit patient-specific 
data, and then others may actually synthesize that patient data through the 
use of algorithms to make automated recommendations for diagnosis and 
treatment.25 Thus, mobile medical apps that interpret patient data for the 
purpose of making critical medical decisions must be finely calibrated and 
monitored closely.26 Otherwise, as health apps continue to multiply, they will 
inadvertently create a new population of mobilechondriacs: consumers 
whose detrimental preoccupation with self-monitoring via mobile medical 
devices and applications leads them to seek excessive and unnecessary 
medical treatment.27 
 
 22. In addition to medical dangers to consumers, transmitting health data over wireless 
networks and via mobile apps presents data privacy concerns under HIPAA. See Kimberly 
Rhodes & Brian Kunis, Walking the Wire in the Wireless World: Legal and Policy Implications of 
Mobile Computing, 16 J. TECH. L. & POL’Y 25, 38 (2011). 
 23. See infra Part II; TIFFANY O’CALLAGHAN, Internet-savvy Patient or “Cyberchondriac”?, 
TIME, Feb. 25, 2010, available at http://healthland.time.com/2010/02/25/internet-savvy-
patient-or-cyberchondriac/print/. 
 24. For example, one study found that the body undergoes physiological changes in blood 
pressure, body temperature, and intraocular pressure when exposed to certain hues of color, 
and that these responses vary based on the preference of an individual. See Hye-Ryeon Jin, et 
al., Study on Physiological Responses to Color Stimulation: Focused on User Centered Design 
Sensibility Engineering Design of Color, INT’L ASS’N SOCIETIES DESIGN RESEARCH 1 (2009). 
 25. See FOOD & DRUG ADMIN., DRAFT GUIDANCE FOR INDUSTRY AND FOOD AND DRUG 
ADMINISTRATION STAFF: MOBILE MEDICAL APPLICATIONS 10-11 (2011) [hereinafter DRAFT 
GUIDANCE] (defining the scope of mobile medical apps to be regulated); U.S. DEPT. OF HEALTH 
& HUMAN SERVS., MOBILE MEDICAL APPLICATIONS: GUIDANCE FOR INDUSTRY AND FOOD AND DRUG 
ADMINISTRATION STAFF 12 (2013) [hereinafter FINAL GUIDANCE], available at http://www.fda.gov/ 
downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM2633
66.pdf. See also infra Part IV.A. 
 26. The FDA has long established Quality Systems requirements with respect to device 
calibration, including automated features. See Food, Drug, & Cosmetics Act, 21 C.F.R. 
§ 820.72 (2004). “Each manufacturer shall ensure that all inspection, measuring, and test 
equipment, including mechanical, automated, or electronic inspection and test equipment, is 
suitable for its intended purposes and is capabale of producing valid results.” Id. 
 27. I created this portmanteau to identify the subset of consumers who are most-likely to 
be at an elevated risk of harm (i.e., misdiagnosis followed by seeking unnecessary medical 
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Part II considers this very real possibility and justifies the need for mobile 
medical app and device developers to mitigate unintended consequences 
for consumers. To be sure, the onus rests largely on the app manufacturer 
to implement quality systems that ensure accurate data measurement and 
interpretation where that data ultimately informs important medical 
decisions.28 The app user must ultimately be empowered to understand the 
implications of collecting individualized biological data on a regular (or 
constant) basis. 
While the United States Food and Drug Administration (FDA) regulates 
medical software and devices based on intended use, the foreseeable risks 
here differ in kind depending on the app’s intended user. Thus, this 
discussion necessitates a distinction between apps intended to be used by 
patient-consumers and those to be used by doctors.29 Part II.A enumerates 
the benefits to patients and consumers using mobile medical apps for self-
quantification and identifies the negative consequences of selling mobile 
medical apps directly to consumers — who may or may not actually need 
them — through the current open-access “app store” marketplaces.30 On 
the other hand, healthcare providers using mobile medical apps face a 
conundrum with respect to “prescribing” software downloads or mobile 
gadgets either as a substitute for traditional medical devices31 or as an 
analytical tool to process patient-reported data.32 Part II.B thus offers a short 
list of foreseeable considerations for healthcare providers in implementing 
mobile medical devices and apps in daily practice.33 Ultimately, as both 
patients and providers expectedly face a considerable learning curve in 
transitioning to the mobile medical paradigm, the question of liability is 
complicated. 
Medical devices of all types, mobile or otherwise, have the potential to 
cause harm due to malfunction, interference, or defective design; this 
applies to both physical and software components of a device. This affirms 
 
treatment) caused by mobile medical apps. In general, the term “cyberchondriac” is used to 
describe “person[s] who fear the worst after using the internet to diagnose [their] ailment[s].” 
Gertrude Block, Language Tips, 82 N.Y. ST. B.A. J. 3, 60 (May 2010). Therefore, a 
“mobilechondriac” is a cyberchondriac whose smartphone enables not only constant internet 
connectivity, but actual health monitoring and diagnosis ability. 
 28. See infra Part II. 
 29. See DRAFT GUIDANCE, supra note 25, at 5 (“Some of these new mobile apps are 
specifically targeted to assisting individuals in their own health and wellness management. 
Other mobile apps are targeted to healthcare providers as tools to improve and facilitate the 
delivery of patient care.”). 
 30. See infra Part II.A. 
 31. See infra Part II.B. 
 32. See infra Part II.B. 
 33. See infra Part II.B. 
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the need for FDA oversight for the sake of protecting consumers, and for 
other checks on app manufacturers, such as a tort action that might 
adequately apportion liability between the doctor, app developer, and 
smartphone manufacturer when a patient relying on an app is harmed by a 
malfunction. 
Prior to issuing its Final Guidance on Mobile Medical Applications, the 
FDA approved a number of apps that it deemed substantially equivalent to 
existing medical devices or software that it had already approved under 
existing regulations and guidance.34 However, for many mobile medical 
apps and accessories in development, the set of foreseeable harms looks 
different than other medical devices operating on independent platforms, 
and until September 2013, the FDA punted the issue for too long.35 
Moreover, many new mobile medical applications and accessories perform 
novel functions when operating on their own or when combined with other 
devices to the extent that the FDA’s substantial equivalence test may be 
inapplicable.36 This makes the faster premarket approval process 
inaccessible to many app developers, forcing them into a cost-prohibitive 
new device application process. Part III summarizes the regulatory scheme 
governing the marketing and manufacture of medical devices prior to the 
Final Guidance and identifies the inadequacies of said rules as applied to 
mobile medical applications and devices.37 
On July 21, 2011 — four years after the first Apple iPhone was released 
— the FDA issued Draft Guidance for Industry and Food and Drug 
Administration Staff on Mobile Medical Applications (Draft Guidance).38 The 
Draft Guidance proposed definitions for mobile platforms, apps, medical 
apps, regulated devices, and mobile medical app manufacturers,39 limiting 
the scope of regulation to apps that either are “used as an accessory to a 
regulated medical device” or “transform a mobile platform into a regulated 
 
 34. See infra Part III. 
 35. See Michele McNickle, mHealth Regulations: Overdue or Overblown?, MHEALTHNEWS 
(June 26, 2012), http://www.mhealthnews.com/news/mhealth-regulations-overdue-or-over 
blown (“It’s easy to see how health IT has lapped the regulatory framework when thinking 
about the amount of IT introduced since the Draft Guidance was released.”). See also Mark 
Crawford, Mobile Medical Applications are a Challenge for the FDA, PILGRIM SOFTWARE BLOG 
(Nov. 11, 2011), http://blog.pilgrimsoftware.com/mobile-medical-applications-are-a-chal 
lenge-for-the-fda/. 
 36. Eric Gilmer, Developing Mobile Apps as Medical Devices: Understanding U.S. 
Government Regulations, IBM.COM (Apr. 16, 2013), http://www.ibm.com/developerworks/ 
mobile/library/mo-fda-med-devices/. 
 37. See infra Part III. 
 38. See DRAFT GUIDANCE, supra note 25. 
 39. Id. at 7-9. See infra Part IV. 
SAINT LOUIS UNIVERSITY SCHOOL OF LAW 
2014] MOBILE MEDICAL APP REGULATION 421 
medical device.”40 Further, acknowledging “the extensive variety of actual 
and potential functions of mobile apps, the rapid pace of innovation in 
mobile apps, and potential benefits and risks to public health,” the FDA 
narrowly tailored its purview to a subset of mobile medical apps that bear 
the traditional functionality of medical devices or those that “impact 
performance or functionality of currently-related devices.”41 In doing so, the 
FDA hoped to regulate mobile medical apps that pose the same types of 
risks to the public as do similar, currently approved medical devices.42 
Following the Draft Guidance came a public notice and comment 
period during which the FDA received over 130 comments from app 
developers, medical device companies, interest groups, doctors, lawyers, 
and government agencies all weighed in before the close of the comment 
period, most of which urged limiting regulation for the sake of innovation.43 
The FDA then delayed issuing the Final Guidance several times much to the 
chagrin of the fast-moving and impatient health technology sector.44 Though 
any guidance from an administrative agency is technically non-binding, 
mobile medical app manufacturers wishing to avoid unexpected and 
expensive federal scrutiny can finally breathe a sigh of relief and move 
forward. 
Part IV introduces the new Final Guidance for mobile medical apps.45 
Therein, Part IV.A outlines the goals, definitions, classifications, and scope 
of the Final Guidance, and provides examples of apps and devices that fall 
within the scope of the new mobile medical app subset, and those that are 
simply mobile health apps.46 Then, Part IV.B argues that because the FDA 
does not want to stifle innovation, and also because it currently lacks the 
 
 40. See DRAFT GUIDANCE, supra note 25. 
 41. Id. at 4. 
 42. Press Release, Food & Drug Admin., FDA Outlines Oversight of Mobile Medical 
Applications (July 19, 2011), available at http://www.fda.gov/newsevents/newsroom/pressan 
nouncements/ucm263340.htm; DRAFT GUIDANCE, supra note 25, at 4. 
 43. Mobile Medical Apps: FDA Issues Final Guidance, MED. NEWS TODAY (Sept. 24, 
2013, 3:00 AM), http://www.medicalnewstoday.com/articles/266479.php. See also DRAFT 
GUIDANCE, supra note 25. See also Letter from Clara Evans, Director, Catholic Healthcare 
West, to Margaret Hamburg, Comm’r, Food and Drug Admin. (Oct. 19, 2011), available at 
http://www.regulations.gov/#!documentDetail;D=FDA-2011-D-0530-0091. This letter 
represents a majority of the public commenters’ concerns on the FDA’s Draft Guidance. See 
also Comment from Robert Andrew Fabich, Public Citizen, REGULATIONS.GOV (Sept. 27, 2011) 
http://www.regulations.gov/#!documentDetail;D=FDA-2011-D-0530-0032 (statement 
represents a majority of the public commenters’ concerns on the FDA’s Draft Guidance). 
 44. Sara Jackson, FDA Mobile Medical App Guidance Faces Delay to 2013, FIERCE 
MOBILE HEALTHCARE (May 28, 2013), http://www.fiercemobilehealthcare.com/story/fda-mo 
bile-medical-app-guidance-faces-delay-2013/2012-05-24. 
 45. See infra Part IV. 
 46. See infra Part IV.A. 
SAINT LOUIS UNIVERSITY SCHOOL OF LAW 
422 SAINT LOUIS UNIVERSITY JOURNAL OF HEALTH LAW & POLICY [Vol. 7:415 
resources and foresight to otherwise impose strict regulations, the new 
guidance ultimately places the onus on mobile medical app manufacturers 
to self-regulate while the FDA keeps watch at arm’s length.47 
For these manufacturers and mobile software developers, the Final 
Guidance leaves many questions unanswered. Part V identifies several 
foreseeable problems the Final Guidance still fails to explicitly address and 
offers practical solutions for manufacturers — especially those software 
companies who find themselves under FDA jurisdiction for the first time — 
seeking to create and market mobile medical apps under the new 
parameters.48 While taking cues from existing regulations might avoid 
disparate standards for evaluating mobile medical apps and devices versus 
traditional medical software and devices, the Final Guidance foreshadows 
adverse procedural and practical consequences that may arise for both app 
manufacturers and for the FDA office tasked with policing compliance, 
approving applications and reporting and tracking adverse events. 
Specifically, Part V argues that the Final Guidance comes with problems 
related to terminology and scope, and fails to approach neither patient-
specific analysis software nor accessories to medical devices and apps. 
Thus, the FDA must overcome significant political and legal hurdles to 
provide efficient, expedient, and dynamic oversight of the coming wave of 
mobile health products, which it may be able to achieve by creating a new 
FDA office in conjunction with the Federal Communications Commission 
specifically for medical software and devices that utilize wireless or 
broadband connectivity.49 
The FDA’s input, though late, is still better than never, considering the 
substantial long-term growth in the mobile health industry. The Final 
Guidance focuses on patient risk awareness and on curbing the potential 
mobilechondriac pandemic. Part VI concludes that the FDA’s new guidance 
is a necessary step toward protecting the consumer from apps that either fail 
to enhance or maintain the consumer’s ability to make informed health 
decisions.50 However, that step alone is not sufficient. Where the FDA’s 
capacity to regulate meets its ultimate lack of resources, it is forced to cast a 
small regulatory net, capturing only a narrow subset of apps that transform 
mobile devices into mobile medical devices, leaving untouched a sea of 
mobile apps that all may have real and possibly serious health 
consequences for users. With increased funding and the passage of key 
 
 47. See infra Part IV.B. 
 48. See infra Part V. 
 49. See Jenny Gold, Lawmaker Pitches New FDA Office of Mobile Health, KAISER HEALTH 
NEWS (Sept. 26, 2012), http://www.kaiserhealthnews.org/stories/2012/september/27/fda-mo 
bile-apps.aspx. See infra Part V. 
 50. See infra Part VI. 
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legislation, the FDA could position itself — namely, by creating a new office 
for mobile medical technologies — to not only educate mobile app 
consumers (i.e., patients and healthcare providers) to use caution and 
discretion when relying on this emerging technology, but also to impose 
labeling and disclaimer restrictions upon mobile app manufacturers whose 
products directly or indirectly aid in the diagnosis, treatment, and 
management of health conditions.51 If nothing else, since consumers of 
mobile medical apps are about to head into a mine of personal biological 
data, the FDA should require mobile medical app manufacturers to plainly 
and expressly disclose the sources of any medical information and 
calculations inside the app, including practical limitations every app 
consumer should know before relying upon the app for medical purposes. 
II.  “MOBILECHONDRIACS” AND THE MOBILE MEDICAL LEARNING CURVE 
A. Self-quantifying from the Patient’s Perspective 
As access to mobile medical apps becomes easier and easier over time 
through numerous outlets, many patients52 will increasingly utilize and even 
rely upon apps and devices to make decisions about their lifestyle, diet, and 
medical care. The total number of smartphones in use worldwide exceeded 
one billion by the end of the third business quarter in 2012.53 This number 
represents one seventh of the global human population,54 and is expected 
to double by 2015.55 The FDA estimates that in 2015, 500 million 
smartphone users will be using at least one healthcare app.56 It is worth 
noting that these figures even exclude internet-enabled tablets.57 
Healthcare apps can range from simple informational programs to body 
mass index calculators, pedometers, pulse monitors, pill-minders, and 
beyond. Some pose more risk to public health than others. By summer 
2013, over 40,000 health-related mobile apps were available for iPhone 
and Android phones.58 Of those, the FDA had granted approval (via its 
premarket approval process) of only 75 new mobile medical apps whose 
intended use was substantially equivalent to a similar approved app or 
 
 51. See infra Part VI. 
 52. I use “patients” interchangeably with “consumers” and “users” here. 
 53. Jun Yang, Smartphones in Use Surpass 1 Billion, Will Double by 2015, BLOOMBERG 
(Oct. 17, 2012, 4:00 AM), http://www.bloomberg.com/news/2012-10-17/smartphones-in-
use-surpass-1-billion-will-double-by-2015.html. 
 54. Id. 
 55. Id. 
 56. See Press Release, Food & Drug Admin., supra note 42. 
 57. Id. 
 58. Gold, supra note 6, at 5D. 
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device.59 These numbers reflect both the recognition by mobile software 
developers of an opportunity to enter the Health Information Technology 
(HIT) market, and the reluctance of the FDA to regulate an ever-broadening 
spectrum of health-related apps with its limited resources for increased 
regulation and enforcement.60 They also reveal that the FDA assumes many 
of the health-related apps on the market pose little to no risk to consumers. 
What remains to be fathomed is the extent to which many apps that are 
seemingly harmless standing alone, may produce harmful results when used 
in combination with other apps to inform their medical decision-making 
process. After all, smartphones and mobile devices are designed to allow 
many apps to be installed and run simultaneously, so a person who 
downloads one of 40,000 health apps is likely to download another: the 
demand expands as quickly as technological innovation.61 
The technological boom not only propelled a new facet of the health 
industry, but it also sparked a “socialized” health movement62 of people 
obsessed with self-measurement for the sake of human optimization. The 
collaborative movement is called “Quantified Self” (QS) and its members 
are dedicated to using (and sometimes making) tools to better understand 
themselves.63 Self-tracking is nothing new, yet thanks to smartphones, 
tablets, and other mobile devices with plenty of built-in and attachable 
sensors (e.g., cameras, accelerometers, gyroscopes, microphones) 
participants can rely on their pocket supercomputers to record, chart, and 
analyze their diet, exercise, mood,64 productivity, sleep — anything.65 Scores 
 
 59. See Dolan, supra note 9. See also Gilmer, supra note 36 (explaining apps with 501k 
clearances are “substantially equivalent to other devices on the market”). 
 60. See David C. Vladeck, The FDA and Deference Lost: A Self-Inflicted Wound or the 
Product of a Wounded Agency? A Response to Professor O’Reilly, 93 CORNELL L. REV. 981 
(2008) (“The FDA is chronically underfunded, overworked, incapable of effectively tackling the 
massive job Congress assigned it, and bereft of the leadership needed to defend itself in the 
court of public opinion.”); Id. at 983. See also DRAFT GUIDANCE, supra note 25, at 10-11 
(citing examples of health-related apps that the FDA does not currently seek to regulate). 
 61. See How Smartphones are on the Verge of Taking over the World, N.Y. DAILY NEWS, 
Mar. 22, 2013, http://www.nydailynews.com/life-style/smartphones-world-article-1.12959 
27. 
 62. Not to be confused with the hot-button catch phrase “socialized medicine” frequently 
used to attack the Patient Protection and Affordable Care Act, or “Obamacare.” See, e.g., 
David Greenberg, Who’s Afraid of Socialized Medicine? Two Dangerous Words that Kill 
Health Care Reform, SLATE (Oct. 8, 2007, 1:20 PM), http://www.slate.com/articles/news_ 
and_politics/history_lesson/2007/10/whos_afraid_of_socialized_medicine.html. 
 63. About the Quantified Self, QUANTIFIEDSELF.COM, http://quantifiedself.com/about/ (last 
visited Jan. 25, 2013). 
 64. See, e.g., Ernesto Ramirez, Toolmaker Talk: Jonathan Cohen (Expereal), 
QUANTIFIEDSELF.COM (Oct. 16, 2012), http://quantifiedself.com/2012/10/toolmaker-talk-jon 
athan-cohen-expereal/. 
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of these mobile device supplements are marketed as “health and fitness” 
apps in the iTunes App Store,66 and many are available for free for all Apple 
mobile device users. The data collected by each individual app can 
illuminate patterns in personal health and habit with real, medical decision-
making implications. 
The self-tracking coin has two sides, though. Because there are not 
currently restrictions barring consumers from purchasing unneeded mobile 
medical apps,67 the market is open to anyone with a smartphone or tablet 
with internet access. For example, the iTunes App Store features a specific 
“medical” app category in its online catalogue. Therein, shoppers can select 
from several categories a button labeled “Apps for Healthcare 
Professionals.”68 Next appears a list of several categories with over 70 apps 
for iPhone and iPad.69 The store demands no verification of medical 
credentials or license, and some of the apps are available for free. Others 
are much more expensive, and their cost alone may be a barrier to exclude 
many non-medical professionals from using the more sophisticated apps. 
Ultimately, since not all technology users are super-savvy (this author 
included), and since there are no access barriers between apps for medical 
professionals and those for everyday consumers,70 a curious smartphone 
user could download a confusing app that might lead them to make 
misinformed health care decisions. With instant access to apps clearly 
designed to perform medical functions, new medical app users may learn 
too much information about themselves without knowing how to process it 
all. 
Alternatively, health apps intended for use by the general population are 
much more widely available than those marketed specifically for medical 
use or for use by medical professionals. While the principle of caveat 
 
 65. The group has a searchable online guide with almost 600 apps and gadgets for self-
quantification. See Quantified Self Guide, QUANTIFIEDSELF.COM, http://quantifiedself.com/ 
guide/ (last visited Jan. 25, 2013). 
 66. iTunes App Store, APPLE.COM, https://itunes.apple.com/us/genre/ios-health-fitness/id 
6013?mt=8 (last visited Jan. 25, 2013). 
 67. Benjamin A. Rosser & Christopher Eccleston, Smartphone Applications for Pain 
Management, 17 J. TELEMEDICINE & TELECARE 308, 312 (2011). 
 68. iTunes App Store, APPLE.COM, https://itunes.apple.com/us/genre/ios-medical/id60 
20?mt=8 (last visited Feb. 18, 2013). 
 69. Categories include EMR & Patient Monitoring, Imaging, Medical Education, Nursing, 
Patient Education, Personal Care, and Reference apps. iTunes App Store, supra note 68. 
 70. Compared to Apple iTunes, the “Google Play” app marketplace does not even 
distinguish between apps intended for medical professionals and those intended for everyday 
users. See Medical Apps, GOOGLE PLAY, https://play.google.com/store/search?q=medical&c 
=apps (last visited Feb. 19, 2013). 
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emptor71 is certainly applicable to consumers relying on mobile apps for 
medical decisions, the app markets (like most internet-based marketplaces) 
do have a built-in protection in the form of scaled app rating systems 
(iTunes uses a five-star rating scale, for example) and user reviews — a kind 
of crowdsourced filter that elevates the products that work and buries those 
that do not. This infrastructure serves as an informal adverse event reporting 
system that could prove to be quite advantageous to the FDA as it begins to 
monitor the safety of mobile medical apps. 
Increasing patient participation in health decisions can improve 
outcomes.72 This participation depends on patient access to relevant and 
reliable health information. According to a 2011 study, “[e]ight in ten 
internet users looked online for health information in 2002 and the same 
proportion [did] so [in 2007] . . . . What has changed is who has access to 
the internet.”73 The troubling statistic, however, is that 75% of those seeking 
medical and health information online fail to look for “quality indicators 
such as the validity of the source” or whether the information created and 
posted is timely and still valid.74 
Problems with information validity are found in the mobile health app 
market as well. In a study of pain management apps in 2011, Benjamin 
Rosser and Christopher Eccleston from the University of Bath Centre for Pain 
Research in the United Kingdom found that “of the [111] apps reviewed, 
86% reported no health-care professional involvement, either directly as the 
app creator or indirectly as a source of information or evaluation of app 
content” and only 12% were reportedly authored by a physician.75 Rosser 
and Eccleston urged that the deficiency of health professionals involved in 
creating pain management and other medical apps raised two main 
concerns: that “self-management should be considered a collaboration 
between patient and health-care professional. . .” and that “of the existing 
apps, there are few reports of the origin of content and validity.”76 Access to 
information certainly empowers patients, especially those who have not 
 
 71. “Let the buyer beware” in Latin. Caveat Emptor Definition, MERRIAMWEBSTER.COM, 
http://www.merriam-webster.com/dictionary/caveat%20emptor (last visited Feb. 18, 2013). 
 72. See, e.g., Robert J. Adams, Improving Health Outcomes with Better Patient 
Understanding and Education, RISK MGMT. & HEALTHCARE POL’Y, Oct. 2010, at 61, available 
at http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3270921/pdf/rmhp-3-061.pdf. 
 73. SUSANNAH FOX, PEW INTERNET & AMERICAN LIFE PROJECT, HEALTH TOPICS: 80% OF 
INTERNET USERS LOOK FOR HEALTH INFORMATION ONLINE 9 (2011), available at http://www.pe 
winternet.org/~/media//Files/Reports/2011/PIP_Health_Topics.pdf. 
 74. RYEN WHITE & ERIC HORVITZ, MICROSOFT RESEARCH, CYBERCHONDRIA: STUDIES OF 
ESCALATION OF MEDICAL CONCERNS IN WEB SEARCH 2 (2008), available at http://research. 
microsoft.com/pubs/76529/TR-2008-178.pdf. 
 75. Rosser & Eccleston, supra note 67, at 311. 
 76. Id. at 312. 
SAINT LOUIS UNIVERSITY SCHOOL OF LAW 
2014] MOBILE MEDICAL APP REGULATION 427 
established a rapport with a doctor, and also those who do not have a 
primary care physician whatsoever. For those who have established 
relationships with health care providers, the relationships are not of 
“deference of information or responsibility, but transference of expertise and 
useful skills.”77 Though the study found that “[i]n general, there is little 
evidence to support the use of pain apps,” it uncovered a great need for 
more involvement from knowledgeable health care professionals in the app 
development process to ultimately benefit and protect the app consumer.78 
But when the internet is the ultimate disseminator of typically unverified 
medical information — misleading or not — it is tempting to self-diagnose 
and easy to get it wrong. 
Many illnesses can manifest the same set of symptoms, but a complete 
diagnosis requires more than simply checking off boxes in a list; it requires 
learned intuition. Similarly, just like a search engine uses algorithms to 
produce the seemingly most-relevant results, even a sophisticated mobile 
medical app must be programmed to anticipate an endless, dynamic list of 
medical possibilities in order to perform effectively. Otherwise, the app 
meant to improve the user’s quality of health could effectually turn the user 
into a mobilechondriac. For example, suppose a person experienced 
frequent throbbing pain in his forehead region. Frustrated, he decided to 
diagnose his symptoms using a “symptom checker” app79 he downloaded 
for free. After indicating his symptoms, a list of 63 possible ailments 
appeared, ranked in order from most-likely to least-likely. The first five 
results were all expected: acute sinusitis, tension headache, cluster 
headache, migraine headache, and chronic sinusitis. But the rest of the list 
bore some terrifying, albeit probably remote, possibilities. “High blood 
pressure” was number six on the list. “Brain aneurysm” was number seven. 
Down the list: diabetes type I, lupus, multiple sclerosis, brain infection, 
cyanide poisoning, plague, bird flu, radiation sickness, and West Nile virus, 
to name a handful. Because the app is designed to display all possible 
results given the user-defined symptoms, the symptom checker app does not 
rule out any potential cause, whereas a physician is able to examine and 
gather more information to make a much narrower diagnosis. 
Also buried in the results of possible ailments is “caffeine withdrawal,” 
which might be common for many coffee-drinking adults. This is something 
a physician might have been able to ask in person. Perhaps the app 
developer could have included dietary habits in the initial symptom 
 
 77. Id. 
 78. Id. at 311. 
 79. WebMD SymptomChecker, WEBMD, http://symptoms.webmd.com/#./symptomsView 
(last visited Feb. 19, 2013). The online version utilizes the same symptom database as the 
phone app. 
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questionnaire. But what about caffeine-free users? Not knowing whether a 
headache is just a sinus problem or a brain tumor, the user might feel 
compelled to seek immediate medical care in the emergency room.80 Also 
consider the inverse, where the user actually has a serious illness like a brain 
tumor but dismisses it as sinusitis based on the mobile app results. 
Even when a health app expressly disclaims its reliability or accuracy, the 
average app consumer is still disadvantaged. This is called “informational 
asymmetry” between patient and doctor.81 While the patient may feel 
empowered by the availability of medical information on his smartphone or 
tablet, the doctor has the experience and formal education to exact 
meaningful diagnosis and treatment decisions. The doctor also hopefully 
has the sense not to recite a list of every possible affliction to a worried 
patient. But when mobile medical apps do more than simply dump 
information into the user’s palm — like an app that gathers individualized 
data and then manipulates the data in some unique way to make an 
automated medical recommendation or drug dosage calculation — the 
danger is much more real. Overall, the benefits to most outweigh the extra 
cost to the select few, but safeguards should be in place to mitigate the risk 
to app consumers who become inadvertent mobilechondriacs. 
B. Download This Mobile Medical App and Text Me in the Morning 
Without breaching the discussion of traditionalism versus ageism, 
mobile technology obviates a generational divide among older doctors and 
those fresh out of medical school.82 The older generation of medical 
students learned that the physician was the “unambiguous source of medical 
knowledge;”83 today, young doctors carry smartphones and tablets packed 
with digital references and dosage calculators on their grand rounds.84 The 
sea change in medical education from the doctor’s point of view has 
logically changed the practice of medicine;85 whether that is a positive thing 
or not is for another paper. Though there are many who resist going digital, 
“[o]lder doctors admire, even envy, their young colleagues’ ease with new 
 
 80. See Zachary Meisel & Jesse Pines, The Allure of the One-Stop Shop: The Real 
Reasons Why People Go to the E.R. when they Shouldn’t, SLATE (Sept. 12, 2008, 7:06 A.M.), 
http://www.slate.com/articles/health_and_science/medical_examiner/2008/09/the_allure_of
_the_onestop_shop.single.html. 
 81. Id. 
 82. Katie Hafner, Redefining Medicine with Apps and iPads, N.Y. TIMES, Oct. 9, 
2012, http://www.nytimes.com/2012/10/09/science/redefining-medicine-with-apps-and-i 
pads-the-digital-doctor.html?pagewanted=all&_r=0. 
 83. Id. 
 84. Id. 
 85. Id. 
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technology.”86 That said, there is a definite learning curve not only for 
patients,87 but also for doctors as well.88 As one doctor noted, “Just adding 
an app won’t necessarily make people better doctors or more caring 
clinicians . . . . What we need to learn is how to use technology to be better, 
more humane professionals.”89 Using apps to improve doctor-patient 
relationships can improve quality of care, which in turn can reduce a 
doctor’s civil liability for malpractice claims from aggrieved patients.90 
But doctors who adopt new mobile medical app technology in their 
practice should be quite selective in choosing apps that actually work as 
intended. Otherwise, relying on or “prescribing” apps to patients that turn 
out to be harmful could be considered a significant departure from the 
reasonable standard of care, putting the doctor in a position of malpractice 
liability. In tort law, a regular person can be held liable for damages under 
a negligence claim when he had a duty (also called a “standard of care”), 
breached that duty, and his breach was the proximate cause (in most cases) 
of harm (damages) to someone else.91 Each element is necessary to a 
complete negligence claim, but once a duty is established, the question of 
breach is typically measured by an objective standard of what a reasonably 
prudent person would do. That is, of course, unless the parties have some 
other special relationship, as do doctor and patient.92 
Doctors, unlike their reasonably prudent patients,93 are in a slightly 
different situation with respect to incorporating medical apps into their own 
practice because they are held to a higher standard of reasonableness.94 
Breaching that duty can sometimes mean using unorthodox techniques, 
medications, or devices; there, the departure would be considered a 
 
 86. Id. 
 87. See supra Part II.A. 
 88. See Hafner, supra note 82. 
 89. Id. (quoting Palo Alto Medical Foundation’s chief innovation and technology officer 
Paul C. Tang). 
 90. See Laura Blue, Better Bedside Manners, TIME, Sep. 05, 2007, available at 
http://www.time.com/time/health/article/0,8599,1659065,00.html (describing a study of 
physician-patient interaction which found that doctors with poor bedside manners received a 
disproportionate number of complaints than those with better communication skills). 
 91. The case Blyth v. Birmingham Waterworks Co. is the classic case defining negligence: 
“Negligence is the omission to do something which a reasonable man, guided upon those 
considerations which ordinarily regulate the conduct of human affairs, would do, or doing 
something which a prudent and reasonable man would not do.” (1856) 11 Exch. 781, 784. 
 92. See Doherty v. Hellman, 547 N.E.2d 931, 933 (Mass. 1989); Flynn v. Bausch, 469 
N.W.2d 125, 128 (Neb. 1991). 
 93. See Vaughn v. Menlove, (1837) 132 Eng. Rep. 490. The reasonably prudent person 
“acts sensibly, does things without serious delay, and takes proper but not excessive 
precautions.” BLACK’S LAW DICTIONARY 1380 (9th ed. 2009). 
 94. See Hall v. Hilbun, 466 So.2d 856, 873 (Miss. 1985). 
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medical judgment that is less than minimally adequate.95 Hall v. Hilbun 
established a national standard for determining a physician’s “non-
delegable duty of care,” as follows: 
[G]iven the circumstances of each patient, each physician has a duty to use 
his or her knowledge and therewith treat through maximum reasonable 
medical recovery, each patient, with such reasonable diligence, skill, 
competence, and prudence as are practiced by minimally competent 
physicians in the same specialty or general field of practice throughout the 
United States, who have available to them the same general facilities, 
services, equipment and options.96 
Though this standard of care does not seem particularly groundbreaking 
30-plus years later, it is worth noting that in the same holding, the 1985 
Mississippi Supreme Court clairvoyantly observed that “[p]hysicians are far 
more mobile than they once were. . .” with “ready access to professional 
and scientific journals . . . for continuing medical education from across the 
country.”97 
Equally important to this discussion of mobile medical technology is that 
the Hall court carved out an exception for the “old locality rule,” which 
serves as a caveat to the nationwide standard.98 Essentially, the court 
acknowledged that given the disparate quality and availability of medical 
tools between rural and metropolitan hospitals, a physician is only as good 
as his tools.99 Thus, a doctor is required to understand the limitations of his 
equipment, facility, and skills, and must “exercise minimally adequate 
medical judgment” consistent with the medical judgment that informs 
similarly-situated physicians across the United States.100 
Applying the Hall standard of care today, a rural doctor with wireless 
internet access on her mobile device could become better able to affordably 
acquire, understand, and implement practices used by other similarly-
situated doctors in larger cities.101 Essentially, mobile-based medical 
solutions may someday be the floor, not the ceiling, of modernized private 
physician practice. The advantages to incorporating mobile medical apps 
and devices into patient care in this context extend well beyond a significant 
reduction in overhead cost. 
 
 95. Id. at 871. 
 96. Id. 
 97. Id. at 870. 
 98. Id. at 872 (emphasis added). 
 99. Hall v. Hilbun, 466 So.2d at 872. 
 100. Id. 
 101. To view multiple maps depicting 3G wireless coverage in the United States by service 
provider, see 3G Network Comparison: AT&T, Cricket, Metro PCS, Sprint, T-Mobile, US 
Cellular & Verizon, CELLULARMAPS.COM, http://www.cellularmaps.com/3g_compare.shtml (last 
visited Jan. 25, 2013) [hereinafter 3G Network Comparison]. 
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Even more, if that doctor prescribes mobile medical apps to several 
patients (i.e. those who have smartphones), then she could collect their data 
wirelessly for on-demand analysis or even real-time alerts for medical 
emergencies.102 The resultant data could be used to make both 
individualized and practice-wide observations and diagnoses about the 
health of a doctor’s community with the larger goal of improving quality and 
access. Some “patients are even working together with physicians and 
scientists to conduct experiments, pooling their data for analysis that may 
shed light on the cause or best treatment for their [common] disease.”103 
Empowering doctors and patients to conduct their own studies within a 
practice or a community at relatively low costs could simultaneously foster 
community-wide health improvement and could serve the dual purpose of a 
small post-market study for the actual medical apps used.104 
Moreover, some physicians even test the new technology on themselves 
first, assuming the risk on an individual basis.105 But a doctor who injures a 
patient by misdiagnosis due to errant medical app data or app malfunction 
is a much greater concern both for the FDA and for injured persons seeking 
common law remedies.106 For informational apps, developers will likely seek 
to absolve themselves from liability to those “mobilechondriacs” with a 
disclaimer reading something to the effect of, “this app is meant for 
informational use only and is not intended to aid in the diagnosis, treatment, 
or prevention of disease” that either appears when the app is engaged, or in 
the very least is pasted into the terms and conditions the user must accept 
before using their newly-downloaded app. In fact, they may encounter 
something similar to the disclaimer utilized by WebMD, one popular 
medical information internet site, which reads: 
The contents of the WebMD Site, such as text, graphics, images, and other 
material contained on the WebMD Site (“Content”) are for informational 
purposes only. The Content is not intended to be a substitute for 
professional medical advice, diagnosis, or treatment. Always seek the advice 
of your physician or other qualified health provider with any questions you 
may have regarding a medical condition. Never disregard professional 
 
 102. See Matt Richtel, Apps that Can Alert the Doctor when Trouble Looms, N.Y. TIMES, 
Oct. 9, 2012, at D3. 
 103. Jeffrey Norris, Self-Tracking May become Key Element of Personalized Medicine, 
UNIV. CAL. SAN FRANCISCO (Oct. 5, 2012), http://www.ucsf.edu/news/2012/10/12913/self-
tracking-may-become-key-element-personalized-medicine. 
 104. Id. 
 105. Id. 
 106. Id. 
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medical advice or delay in seeking it because of something you have read 
on the WebMD Site!107 
There, the words “for informational purposes only” and “not intended to be 
a substitute” (for a physician’s advice) may be satisfactory for a website that 
simply displays an aggregate of medical information. The disclaimer above 
not only attempts to educate the WebMD visitor that a medical problem 
warrants inspection by a medical professional, but also seeks to absolve 
WebMD from claims of fraudulent misrepresentation or even medical 
malpractice, which can be brought in situations where a patient-physician 
relationship has been established (even between a website and an internet 
user).108 
Alone, even a keenly-worded disclaimer is insufficient for mobile apps 
providing information plus a unique function, especially since the legal 
effect of a disclaimer on the internet is still a disputed issue.109 Disclaimer or 
not, an app not advertised as “medical” can prove to be medically 
significant to a patient who, as a result of using the app as directed, lowers 
his cholesterol or even remembers to take his medication on time. Non-
medical apps help consumers remember to take medication,110 make health 
dietary choices,111 exercise,112 or quit smoking.113 After all, is not the 
primary reason for using any health-related app to prevent the onset of 
obesity, diabetes, heart disease, and other maladies tied to diet and overall 
health habits? The questions of liability and remedy remain for patients who 
 
 107. Additional Information, WEBMD, http://www.webmd.com/about-webmd-policies/add 
itional-info?ss=ftr (last visited Feb. 18, 2013). The following paragraph in the disclaimer 
reads: “If you think you may have a medical emergency, call your doctor or 911 immediately. 
WebMD does not recommend or endorse any specific tests, physicians, products, procedures, 
opinions, or other information that may be mentioned on the Site. Reliance on any information 
provided by WebMD, WebMD employees, others appearing on the Site at the invitation of 
WebMD, or other visitors to the Site is solely at your own risk.” Id. 
 108. See Philip M. Kober, Regulating Medicine on the Internet, WIS. LAWYER, Feb. 2010, at 
10. See also infra Part II.B. 
 109. Kober, supra note 108, at 12. “Clearly stated, prominent disclaimers should be used 
to prevent over-reliance on such Web sites. However, self-help and other Web sites that simply 
provide information are not a substitute for seeking the advice of one’s own physician, and the 
legal enforceability of such disclaimers remains unclear.” Id. 
 110. iTunes App Store, APPLE.COM, https://itunes.apple.com/us/app/medcoach-medica 
tion-reminder/id443065594?mt=8 (last visited Jan. 25, 2013). 
 111. Raechel Conover, 4 Best Diet Apps to Help You Lose Weight, CHEAPISM (Jan. 21, 
2013, 11:12 AM), http://www.cheapism.com/blog/2367/diet-apps. 
 112. Lisa Freedman, Best Fitness and Nutrition Apps for iPhone, MENS FITNESS (Jan. 2013), 
available at http://www.mensfitness.com/training/best-fitness-and-nutrition-apps-for-iphone. 
 113. Kimberly Holland, The 11 Best Quit Smoking iPhone and Android Apps of 2013, 
HEALTHLINE (Aug. 9, 2013), http://www.healthline.com/health-slideshow/top-iphone-android-
apps-quit-smoking. 
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suffer injury or death resulting from an app developer’s digital negligence; 
the injured patient may not have a medical malpractice remedy if it cannot 
establish a patient-doctor relationship with the digital doctor.114 
While a tort claim might be one option for the patient, a doctor relying 
on a defective mobile medical app may be able to bring a fraudulent 
misrepresentation claim under contract law against the app developer who 
marketed the app with specific claims for its intended medical use. However, 
this typically requires proving that the developer knew or should have known 
its claims were false.115 Yet even these claims may not work where the 
developer has issued a disclaimer with respect to the physician’s claim at 
issue.116 
Further, who is liable for an injury to a patient resulting from some 
malfunction outside the app itself? Since smartphones are designed as 
multi-function computers with the capability to not only make telephone 
calls but also to host dozens if not hundreds of different apps, depending on 
them for constant monitoring or accurate information transmission carries a 
new set of dangers. For example, a patient utilizing a smartphone app that 
transmits information to his doctor may receive a phone call that interrupts 
or interferes with the collection or transmission of data. The possibility for 
other apps to interfere with each other is also present, as many can send 
“push notifications” which interrupt any app currently in use with a message 
that must be dismissed before resuming intended app use. There are also 
general connectivity issues for people in rural areas or coverage dead 
zones, who may not be able to send and receive critical information from 
their apps due to broadband limitations or lack of access to a cellular data 
network.117 
Finally, the sensors embedded in the phone itself (or even the operating 
system) may malfunction, and then apps that depend on those sensors will 
follow suit. When this happens as a result of a defect in the phone, is the 
phone manufacturer now liable in the same way a manufacturer of a 
 
 114. Kober, supra note 108. 
 115. The elements of a misrepresentation claim are outlined in the software case Step-
Saver Data Systems v. Wyse Technology, which has become a staple in contract law 
casebooks. 939 F.2d 91 (3d Cir. 1991). They are: “(1) a material misrepresentation; (2) an 
intention to deceive; (3) an intention to induce reliance; (4) justifiable reliance by the recipient 
upon the representation; and (5) damage to the recipient proximately caused by the 
misrepresentation.” Id. at 106. 
 116. See, e.g., i2 Technologies, Inc. v. DARC Corp., No. 02-CV-0327-H, 2003 WL 
22205091 (N.D. Tex. Sept. 23, 2003) (holding that where claims of fraudulent 
misrepresentations are made about a software’s capabilities, those claims are precluded by a 
disclaimer to the same effect, and that the disclaimer defeats the reliance element of such an 
inducement claim). 
 117. See 3G Network Comparison, supra note 101. 
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pacemaker would be if it became defective and caused a heart attack? 
While the FDA may not be able to regulate the marketing and manufacture 
of the smartphones themselves, mobile medical app and accessory 
manufacturers should mitigate the risks of relying wholly on a platform 
created by someone else by building in safeguards to prevent interference 
and software incompatibility. One way to do this is by contractually 
requiring component and platform manufacturers to comply with Quality 
Systems regulations, discussed further in Part IV.B.118 In short, obtaining 
more health information is important for the patient and doctor alike, but 
the information must be accurate, relevant, and verified, or it will lead to 
errant self-diagnoses by consumers and misdiagnoses (or missed-diagnoses) 
by doctors, the result of which could be harmless or quite serious, 
depending on the app itself and its intended use. 
III.  REGULATING NEW TECHNOLOGY WITH OLD RULES: PREMARKET NOTIFICATION, 
APPROVAL, AND THE CURRENT SPECTRUM OF AVAILABLE MOBILE MEDICAL APPS 
The iPhone was first introduced in 2007119 and the first mobile medical 
app was submitted for premarket approval in February 2011.120 Since then, 
over 40,000 health-related apps have been made available for 
download.121 During this period of time, the FDA either declined to regulate 
mobile medical apps that did not pose an immediate risk,122 or alternatively 
granted premarket approval using existing regulations and guidance for 
medical software and already-approved medical devices.123 As innovation 
 
 118. See BRADLEY M. THOMPSON, FDA REGULATION OF MOBILE HEALTH 8-9 (2010), 
available at http://mobihealthnews.com/wp-content/pdf/FDA_Regulation_of_Mobile_ 
Health.pdf (“In the medical device world, component suppliers are exempt from [Quality 
Systems and Design Control] requirements (though sometimes they are contractually 
required. . . . [This] means that the finished device manufacturer has the regulatory burden of 
assuring the quality of the components it uses.”). See also infra Part IV.B. 
 119. Apple, iPhone, APPLE-HISTORY, http://apple-history.com/iphone (last updated Aug. 26, 
2012). 
 120. “Mobile MIM” for iPhone was the first mobile medical app approved by the FDA. See 
Mike Luttrell, Medical iPhone App is FDA Approved, TGDAILY.COM, (Feb. 7, 2011), 
http://www.tgdaily.com/mobility-brief/53973-medical-iphone-app-is-fda-approved. The app, 
which is “used for the viewing, registration, fusion, and/or display for diagnosis of medical 
images” is now available in the Apple iTunes App Store for free at https://itunes.apple.com/ 
us/app/mobile-mim/id281922769?mt=8. 
 121. Jenny Gold, FDA Regulators Face Daunting Task as Health Apps Multiply, USA 
TODAY (June 27, 2012), available at http://usatoday30.usatoday.com/news/health/story/ 
2012-06-22/health-apps-regulation/55766260/1. 
 122. See Press Release, Food & Drug Admin., supra note 42. 
 123. The FDA based its guidance on existing regulations for medical device data systems, 
medical software, quality systems, and its classification system under the FD&C Act. See DRAFT 
GUIDANCE, supra note 25, at 12 & n.16; FINAL GUIDANCE, supra note 25, at 13 & n.21. 
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quickly outpaced government action, contentions naturally festered between 
eager mobile medical app developers and the hesitant FDA. Initially, the 
apps that received premarket approval under the existing regulations were 
relatively safe bets for FDA preapproval because they represented the 
substantial equivalent function of already-approved medical devices and 
software.124 
The existing premarket notification regulations for medical devices found 
in section 510(k) of the Food and Drug Administration Modernization Act of 
1997 (FDAMA)125 already allowed device manufacturers to speed up the 
approval process before marketing a new medical device if the new device 
was substantially equivalent to a previously-approved device.126 Device 
manufacturers (or distributors) must file a premarket notification with the 
FDA no fewer than 90 days before the device is released and distributed.127 
From this notification, the FDA “may issue an order of substantial 
equivalence only upon making a determination that the device . . . is as safe 
and effective as a legally marketed device.”128 Since not all devices pose the 
same risk to the general public, however, the evaluation criteria for 
determining substantial equivalence are divided into three classes.129 
Devices that pose a low risk to the health and safety of the general public 
fall under Class I, and the FDA will grant a determination of substantial 
equivalence “based primarily on descriptive information and a labeling 
review” for most devices in this category.130 In fact, because of the low risk 
involved, many generic Class I devices are now exempt from the premarket 
notification process altogether, “unless the device is intended for a use that 
is of substantial importance in preventing impairment to human health or 
presents a potential unreasonable risk of illness or injury.”131 Some Class II 
generic devices have also been deemed exempt from premarket 
 
 124. Dolan, supra note 10. See also CTR. FOR DEVICES & RADIOLOGICAL HEALTH, FOOD & 
DRUG ADMIN., THE NEW 510(K) PARADIGM: ALTERNATE APPROACHES TO DEMONSTRATING 
SUBSTANTIAL EQUIVALENCE IN PREMARKET NOTIFICATIONS 2 (1998) [hereinafter 510(K) 
PARADIGM], available at http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationand 
Guidance/GuidanceDocuments/ucm080189.pdf (outlining final guidance for the premarket 
notification exemption process for Class I devices, except those devices that are “intended for 
a use that is of substantial importance in preventing impairment to human health” or those 
that “present[] a potential unreasonable risk of illness or injury”). 
 125. Food and Drug Modernization Act of 1997, Pub. L. No. 105-115, 111 Stat. 2296 
(codified at 21 U.S.C. § 301 et seq.). 
 126. 510(K) PARADIGM, supra note 124, at 1. 
 127. Id. The premarket notification content requirements can be found at 21 C.F.R. 
807.87. Premarket Notification Procedures, 21 C.F.R. § 807.87 (2001). 
 128. 510(K) PARADIGM, supra note 124, at 1. 
 129. Id. at 1-2. 
 130. Id. at 1. 
 131. Id. at 2. 
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notification.132 These pose a greater risk than Class I exempt devices, but 
can still be approved as substantial equivalents to existing medical devices. 
Class III devices include those “for which general controls and special 
controls are insufficient to provide reasonable assurance of the safety and 
effectiveness of a device . . . .”133 These Class III devices typically “intended 
to be used in supporting or sustaining human life or preventing impairment 
of human health, or that may present a potential unreasonable risk of illness 
or injury . . . .”134 All Class I devices are subject to General Control 
requirements;135 Class II devices are subject to additional Special 
Controls;136 and Class III devices must undergo full “scientific review” 
through the premarket approval (PMA) process before being marketed.137 
The time it takes to process a premarket notification correlates to the risk 
involved. To submit a premarket notification for a no-risk-to-low-risk device 
that will fall under Class I (an “exempt” version of an already-approved 
device), the app developer can register the device with the FDA,138 pay a 
fee,139 and expect clearance within five to seven business days, and no 
 
 132. Id. See also Medical Devices; Exemptions From Premarket Notifications; Class II 
Devices, 63 Fed. Reg. 3, 142 (Jan. 21, 1998). 
 133. Medical Devices: Regulatory Controls, FOOD & DRUG ADMIN., http://www.fda.gov/ 
MedicalDevices/DeviceRegulationandGuidance/Overview/GeneralandSpecialControls/ (last 
updated Apr. 11, 2013) [hereinafter Regulatory Controls]. See also 510(K) PARADIGM, supra 
note 124, at 2. 
 134. Regulatory Controls, supra note 133. 
 135. Id. 
 136. Id. 
 137. Id.; Medical Devices: Premarket Approval (PMA), FOOD & DRUG ADMIN., 
http://www.fda.gov/medicaldevices/deviceregulationandguidance/howtomarketyourdevice/ 
premarketsubmissions/premarketapprovalpma/ (last updated Jan. 24, 2012). 
 138. The FDA has an online system for this process. FDA Industry Systems, FOOD & DRUG 
ADMIN., https://www.access.fda.gov/oaa/logonFlow.htm;jsessionid=vSMTRsPSh3TZ8dv56ht 
QJjQvF8H0DzL4Jrk8ZTdfs6STTLPG1GZj!-1716739001?execution=e1s1 (last visited Feb. 
26, 2013). 
 139. Device manufacturers and others involved in the marketing of devices must pay “user 
fees” to the FDA to fund the approval process. The current annual user fee (effective October 
1, 2012 to October 1, 2017) is $2,575. David Gartner, Medical Device Establishment 
Registration and Listing – Notice of Changes for FY 2013, FOOD & DRUG ADMIN., 
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/ucm314844.htm (last updated 
Aug. 10, 2012). For a table of who must pay the annual user fees to be involved in the 
manufacturing and marketing of medical devices, see id. The Medical Device User Fee 
Amendments 2012 (MDUFA III) authorized the FDA to collect these fees, which amounts to 
nearly $600 Million over five years. See Medical Device User Fee Amendments 2012 (MDUFA 
III), FOOD & DRUG ADMIN., http://www.fda.gov/MedicalDevices/DeviceRegulationandGuid 
ance/Overview/MDUFAIII/default.htm (last updated Oct. 16, 2013). 
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formal 510(k) premarket approval application is needed.140 An example of 
an exempt Class I device that could be duplicated as a mobile medical app 
is a gustometer used by ear, nose, and throat specialists to stimulate the 
taste buds by touching two electrodes to the tongue,141 which could easily 
be reproduced as combination app and smartphone or tablet attachment. 
For Class II devices that have the same function and intended use as devices 
already on the market, like the recently released ultrasound app and 
attachment,142 the processing time can last between four and ten months.143 
Finally, Class III devices — those with a novel or innovative intended use or 
combination of uses — require the longest amount of processing time, since 
they must be subjected to full premarket approval (PMA) including possible 
clinical trials, a process that takes anywhere from 180 days to 36 months.144 
A smartphone app wirelessly controlling an injectable nano-transmitter that 
delivers a drug on demand or at certain intervals would likely be categorized 
as Class III, since the risk associated with this technology is unknown. 
Regardless of risk classification, all device manufacturers must 
implement Quality Systems protocol, though what that actually looks like in 
practice must be individually tailored to the particular development and 
manufacturing process based on the overall risk associated with the device’s 
intended use.145 For purposes of mobile medical apps, the Quality Systems 
regulations require “Design Controls” for “[d]evices automated with 
computer software.”146 Essentially, this means that a mobile medical app 
developer must create documentation and review procedures from the initial 
planning stages and implement them actively throughout the production 
process. The ultimate result is a well-documented procedure manual 
demonstrating that every detail was considered with the intended use and 
the risks to the patient end user in mind.147 Presumably, app developers 
working primarily with computers can easily implement electronic 
 
 140. Elisa Maldonado Holmertz, Developing a Mobile App? How to Determine if it is a 
Medical Device and get it Cleared by the US FDA, SLIDESHARE, at slides 25-26, available at 
http://www.slideshare.net/emergogroup/the-us-regulatory-approach-to-mobile-medical-apps. 
 141. 21 C.F.R. § 874.1500 (2013). 
 142. See Luke Timmerman, Mobisante Wins FDA Approval for “Ultrasound on a 
Smartphone” Technology, XCONOMY (Feb. 3, 2011), http://www.xconomy.com/seattle/2011/ 
02/03/mobisante-wins-fda-approval-for-ultrasound-on-a-smartphone-technology/?single_ 
page=true. 
 143. Holmertz, supra note 140, at slide 26. 
 144. Id. 
 145. Quality Systems, 21 C.F.R. § 820.5 (2012). 
 146. 21 C.F.R. § 820.30(a)(2)(i) (2012). 
 147. The Quality Systems regulations require several other controls, including Document 
Controls, Production and Process Controls, Purchasing Controls, Labeling and Packaging 
Controls, and more. See 21 C.F.R. §§ 820 et seq. (2012). 
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documentation systems to comply with these requirements and other 
documentation controls. 
For better or worse, the FDA provisionally relied on its existing premarket 
notification and approval process to evaluate medical devices of all types, 
including mobile medical apps.148 The most substantial practical concern 
that arises when using the existing regulations, however, is the disparity 
between the timeline for getting software or a device approved and the 
speed at which smartphone and tablet technology advances. The late Apple 
CEO Steve Jobs said it best in January 2008 (just one year after his 
groundbreaking new smartphone was introduced): “iPhone doesn’t stand 
still — we’re making it better and better all the time.”149 In fact, a new 
iPhone has been released every year since 2007.150 Even more, within the 
lifespan of each new generation of the Apple smartphone, several updates 
to the iPhone operating system (iOS) occur, and older iPhone models are 
phased out of compatibility with each new iOS. This same process occurs 
with apps designed for the Android operating systems and for the Windows 
Mobile operating systems. Thus, each operating system update means a 
new app update, and eventually some older model phones will disallow new 
apps to be installed because the phones are unable to run the latest 
operating system versions.151 In short, app developers seeking long-term 
participation in the mobile market, health-related or otherwise, must 
anticipate the dynamic changes in the mobile platform market to remain 
viable and competitive. So app developers marketing their software or 
accessory with an intended medical use must constantly test, redesign, and 
reimagine medical apps to maintain integrity, functionality, and efficacy in 
order to survive the constant mobile platform updates. 
The 510(k) premarket notification timetable problem becomes even 
more apparent in the context of an FDA regulation that requires device 
manufacturers to seek approval for changes it makes to its device and 
software design, including labeling and marketing changes.152 Given that 
 
 148. Food and Drug Modernization Act of 1997, Pub. L. No. 105-115, 111 Stat. 2296 
(codified at 21 U.S.C. § 301 et seq.). 
 149. Press Release, Apple, Apple Enhances New Revolutionary iPhone with Software 
Update (Jan. 15, 2008), http://www.apple.com/pr/library/2008/01/15Apple-Enhances-Revo 
lutionary-iPhone-with-Software-Update.html. 
 150. The first generation iPhone was introduced in June 2007; iPhone 3G in June 2008; 
iPhone 3GS in June 2009; iPhone 4 in June 2010; iPhone 4S in October 2011; and the 
iPhone 5 hit the market in September 2012. See Compare Models, APPLEHISTORY.COM 
(2013), http://apple-history.com/compare/iphone_3g/iphone_3gs/iphone_4/iphone_4s. 
 151. Peter Cohen, Here’s Why You Shouldn’t Upgrade to iOS 7. . .Yet, IMORE.COM (Sept. 
17, 2013, 2:38 PM), http://www.imore.com/heres-why-you-shouldnt-upgrade-ios-7-yet. 
 152. See 21 C.F.R. § 807.81(a)(3) (2013); FOOD & DRUG ADMIN., DECIDING WHEN TO 
SUBMIT A 510(K) FOR A CHANGE TO AN EXISTING DEVICE 1 (1997) [hereinafter DECIDING WHEN], 
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apps are updated frequently, the mobile medical app or device 
manufacturer will routinely face the possibility of having to submit a new 
510(k) application for each update it makes. The 510(k) provision at issue 
states that the company marketing a device must submit a new premarket 
notification when the device “is about to be significantly changed or 
modified in design, components, method of manufacture, or intended 
use.”153 A “significant change” is one that “could significantly affect the 
safety or effectiveness of the device” or “a major change or modification in 
the intended use of the device.”154 Practically speaking, not every change to 
a device is “substantial,” so the documentation and protocol requirements 
found in the Good Manufacturing Practices and Quality Systems regulations 
equip the manufacturer, and thereby the FDA on the front end, with the 
information to determine whether the change is substantial.155 The 
manufacturer’s protocol for determining substantial change should consider 
changes to: labeling; technology, engineering, and performance; and 
materials.156 
For mobile medical app developers, where updating the software 
necessitates changing the computer algorithms the app uses for calculating 
medical information, the change could be considered substantial under the 
engineering, performance, and labeling categories.157 Another example of a 
substantial change particularly relevant for mobile medical app updates is a 
change to the control mechanism of the device;158 the mobile platform is a 
control mechanism (including the touchscreen interface and sensors), so 
when an existing app must be updated to work on a new smartphone, it 
may be subject to the substantial change 510(k) filing requirement. This 
process is not free; the standard filing fee for fiscal year 2014 for each 
510(k) application is $5,170 (or $2,585 for small businesses with less than 
or equal to $100 Million in gross receipts or sales per year).159 Add in the 
cost of writing the code for the new updates and testing them for validation 
as required by the Quality Systems standards, and the expenses for small 
developers seem relatively large. 
 
available at http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/ 
GuidanceDocuments/ucm080243.pdf. 
 153. 21 C.F.R. § 807.81(a)(3) (emphasis added). 
 154. Id. 
 155. See DECIDING WHEN, supra note 152, at 3. 
 156. Id. at 7-22. 
 157. Id. 
 158. Id. 
 159. Premarket Notification [510(k)] Review Fees, FOOD & DRUG ADMIN., http://www.fda. 
gov/MedicalDevices/DeviceRegulationandGuidance/HowtoMarketYourDevice/PremarketSub
missions/PremarketNotification510k/ucm134566.htm (last updated Dec. 13, 2013). 
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Because the time to process each 510(k) change application under 
current regulations is quite lengthy relative to the shelf-life of a given mobile 
platform or mobile medical app, and because mobile medical apps are 
meant to be easily updated and ever-improving, the 510(k) scheme for 
premarket notification existing prior to the FDA’s Final Guidance will not 
continue to work for many mobile medical apps, especially those with 
attachments that will generally fall into Class II.160 Though the FDA does 
already have a mechanism called “Special 510(k)” that remedies the 
problem for frequently-updated devices to a certain extent,161 a more 
streamlined process should be created to account for mobile medical apps 
that necessitate frequent updates across multiple mobile platforms. 
Unfortunately, the Final Guidance provides little hope of a fast track for 
mobile apps except for the promise of additional future guidance. 
IV.  FDA FINAL GUIDANCE ON MOBILE MEDICAL APPLICATIONS: 
PROBLEMS AND SOLUTIONS 
A. Final Guidance in a Nutshell: Definitions, Scope, and Classifications 
Drafting effective regulation begins in defining the terminology. The FDA 
Final Guidance provides new definitions for the mobile category of health 
care applications with practical examples for each definition.162 The 
foundational definition is, appropriately, the “mobile platform.” The Final 
Guidance defines mobile platforms as “commercial off-the-shelf (COTS) 
computing platforms, with or without wireless connectivity, that are handheld 
in nature.”163 Devices like the iPhone, Android, and other “mobile 
computers” like tablets or portable computers are sufficient examples of 
platforms with the capability of supporting multiple apps.164 Next, a “mobile 
application” (mobile app) is a “software application that can be executed 
(run) on a mobile platform, . . . or [one that] is tailored to a mobile platform 
but is executed on a server.”165 
But the question on every mobile health app developer’s mind is 
presumably: what makes a mobile application a “mobile medical 
application” and not a mobile health application? The Final Guidance 
 
 160. See 510(K) PARADIGM, supra note 124. 
 161. This process essentially allows the manufacturer to submit a 510(k) premarket 
notification for a substantial change without having to verify internal data to back it up. See 
How to Prepare a Special 510(k), FOOD & DRUG ADMIN. (Dec. 7, 2009), http://www.fda.gov/ 
MedicalDevices/DeviceRegulationandGuidance/HowtoMarketYourDevice/PremarketSubmis 
sions/PremarketNotification510k/ucm134573.htm. 
 162. FINAL GUIDANCE, supra note 25, at 7-11. 
 163. Id. at 7. 
 164. Id. 
 165. Id. 
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offers that a mobile medical app is “a mobile app that meets the definition 
of device in section 201(h) of the Federal Food, Drug, and Cosmetic Act 
(FD&C Act); and either is intended: to be used as an accessory to a 
regulated medical device; or to transform a mobile platform into a 
regulated device.”166 For seasoned medical device manufacturers, this 
might be satisfactory, but to the slew of green-horned app developers 
seeking possible entry into the mobile medical market, the definition 
requires further expedition into the FD&C Act. The definition requires that 
the mobile app suffice as a “device” under section 201(h) of the FD&C 
Act,167 which defines a “device” as: 
an instrument, apparatus, implement, machine, contrivance, implant, in 
vitro reagent, or other similar or related article, including any component, 
part, or accessory which is . . . (2) intended for use in the diagnosis of 
disease or other conditions, or in the cure, mitigation, treatment, or 
prevention of disease, in man or other animals . . . .168 
Just as the intended use of an accessory determines whether an apparatus is 
ultimately deemed a “device,”169 the FDA further suggests that a mobile 
app’s intended use dictates whether it transforms the mobile platform into a 
“device.”170 Manufacturers can demonstrate intended use “by labeling 
claims, advertising materials, or oral or written statements . . . .”171 Mobile 
apps meeting these requirements are considered devices, and those that are 
considered “similar to software designed to run on a desktop computer” are 
regulated under 21 C.F.R. 862.1345.172 
Boiled down, if a mobile app or device is marketed for an intended use 
for medical care, it transforms the mobile platform into a mobile medical 
device subject to FDA regulation. Fortunately, the FDA does not plan to 
regulate all mobile platforms that are capable of supporting mobile medical 
applications and devices, but rather only those mobile platforms that are 
commercially marketed with an intended use of acting as a medical 
device.173 The Final Guidance exempts many app creators: mobile platform 
manufacturers who do not market their products with specific intended 
medical uses, third party marketers of mobile apps and devices, internet 
 
 166. Id. (emphasis added). 
 167. Id. 
 168. Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 321(h) (2006). 
 169. Id. 
 170. DRAFT GUIDANCE, supra note 25, at 7-8; FINAL GUIDANCE, supra note 25, at 7. 
 171. FINAL GUIDANCE, supra note 25, at 8. 
 172. Id. at 7. 
 173. Id. at 10. 
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providers, doctors developing apps for private professional practice, and 
developers making apps for use in research or teaching.174 
So, an Apple or a Samsung will not be directly subject to FDA Good 
Manufacturing Practices requirements nor will they be forced to pay annual 
device user fees175 and submit 510(k) premarket notifications for new 
versions of their smartphones or tablets generally, but if either company 
began marketing it to medical professionals as a platform to improve 
patient outcomes or to aid in the diagnosis, treatment, etc. of a medical 
condition, then the line may be blurred. As such, it is not clear whether 
mobile platform manufacturers may attempt to market their device directly to 
physicians and medical care providers and make any medical claims at all. 
Mobile medical app manufacturers face a similar dilemma: given the 
learning curve for utilizing new apps and devices on a mobile platform, will 
app developers hire “app reps,” much like the pharmaceutical industry, to 
demonstrate the product to health professionals? If so, these “app reps” will 
presumably be subject to the same restrictions on marketing as are 
pharmaceutical and traditional medical device sales representatives.176 
While the Final Guidance excludes the app stores from the definition of 
manufacturer, it does not answer any of these questions related to marketing 
the mobile platform to health care professionals. Thus, the burden falls on 
the mobile medical industry to find its own answers.177 
B. The Mobile Medical Industry Bears the Burden (and Benefit) 
 of Self-regulation 
Because manufacturers and developers have a finger on the rapid pulse 
of mobile medical innovation, and because the FDA will only require 
premarket approval for a narrow scope of mobile medical apps,178 the 
mobile medical industry is in the best position to regulate itself effectively. 
Moreover, the choice of the FDA to issue guidance (at least for now), rather 
than strict and distinct regulations for mobile medical devices, inherently 
places the onus on the industry to implement general controls and to adhere 
to the existing medical device regulations wherever applicable. Given the 
 
 174. See id. at 10-11. 
 175. See id. at 10. 
 176. One example of the FDA’s regulation over drug reps is an adverse-event-reporting-
type system for physicians to report dubious marketing practices by drug companies and drug 
reps, called the “Bad Ad Program.” See Robert Lowes, FDA Urges Physicians to Report 
Misleading Drug Promotions, MEDSCAPE NEWS TODAY (May 11, 2010), http://www.medscape. 
com/viewarticle/721647. 
 177. The Final Guidance encourages mobile medical app developers to affirmatively 
contact the FDA to seek clarification on applicable regulatory requirements. See FINAL 
GUIDANCE, supra note 25, at 12. 
 178. See supra Sections III, IV. 
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FDA’s limited budget and ever-growing plate of responsibilities,179 requiring 
full premarket approval for every new mobile medical app would clog the 
application pipeline to the point where releasing new mobile medical apps 
would be cost-and-time prohibitive. 
Even more, most smartphone apps communicate with their creators 
when problems arise, allowing developers to react within hours or days to 
correct the glitch and publish a new update. Compare that responsive 
system to a traditional device manufacturer with a defective standalone 
product: the manufacturer learns of a defective device by injured parties 
filing lawsuits or directly from the FDA long after the malfunction has 
occurred, and then must expend a great deal of money to repair, replace, 
or recall each device.180 Thereafter, the manufacturer must recoup the cost 
of its mistake by raising prices of future products, further increasing the costs 
of healthcare for doctors, consumers, and insurers. Allowing for a faster-
acting system of recall-and-replace app updating tied to automated glitch 
reporting without the 510(k) substantial change application requirement 
would reduce the cost of recall and dramatically shorten the timetable for 
avoiding harm to the consumer. 
The mobile medical app manufacturers are also best situated to mitigate 
many of the inherent risks of relying on a mobile platform, since they also 
bear the burden of liability to the end user. For instance, the Final Guidance 
exempts mobile platform manufacturers (Apple and its iPhone platform, 
e.g.) from “Quality Systems” requirements to which mobile medical app 
manufacturers must adhere.181 This makes sense from a jurisdictional 
standpoint, since the platform itself is not a medical device182 and is instead 
regulated by the Federal Communications Commission (FCC).183 However, 
this exemption raises the question of who is responsible for unforeseen 
defects within the platform that substantially interfere with the reliability, 
accuracy, and functionality of the FDA-regulated mobile medical apps. 
 
 179. Food and Drug Administration FY 2014 Congressional Budget Request, FOOD & DRUG 
ADMIN. (May 7, 2013), http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Re 
ports/BudgetReports/UCM347422.pdf. 
 180. The FDA regulations for recalls account for voluntary recalls as well as mandatory 
ones. See Recalls, Corrections and Removals (Devices), FOOD & DRUG ADMIN., 
http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/PostmarketRequirements/
RecallsCorrectionsAndRemovals/ (last updated Nov. 16, 2010); 21 C.F.R. § 7 (1977); 21 
C.F.R. § 810 (1996). 
 181. FINAL GUIDANCE, supra note 25, at 10-11. 
 182. See id. at 7, 10. 
 183. The FCC’s Wireless Telecommunications Bureau regulates smartphones and other 
wireless devices, including licensing and bandwidth issues. See Wireless Telecommunications 
Bureau, FED. COMM’N COMM., http://www.fcc.gov/wireless-telecommunications-bureau (last 
visited Feb. 23, 2013). 
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Since the manufacturer has the regulatory obligation to implement Quality 
Systems and Design Controls, it is responsible for ensuring the quality of the 
components it purchases and uses in creating the device.184 Additionally, it 
has the power to choose its own suppliers and the power to influence its 
suppliers to implement quality standards consistent with the device 
manufacturer’s own Quality Systems protocol. This can be accomplished by 
contract, or by simple market competition.185 But considerations for 
bandwidth and connectivity outages are primarily the concern of the FCC 
and the wireless network providers themselves, not the app developers.186 
Ultimately, the mobile medical industry is best equipped to assign 
responsibility to its members and to those capable of bearing the risk, and it 
will reap the benefits of more flexibility in innovation as a result. 
V.  FINAL GUIDANCE: NOT THE FINAL FRONTIER 
The Final Guidance itself contains problems with terminology and 
scope. While it is impossible to know the future of mobile technology, even 
the base definition of “mobile platform” contains problematic phrases like 
“handheld in nature” and “typically used as smartphones” that might 
inadvertently exclude new technologies on the near horizon, since some new 
platforms capable of hosting mobile medical apps are currently in 
development and testing that are not handheld and are not even typically 
used as smartphones. For example, Google expects its “Project Glass” 
research and development project for “wearable computing” — glasses 
lenses that display computerized images — to be sold publicly in 2014.187 
Microsoft recently obtained its own patent on similar “augmented reality” 
wearable computer glasses.188 Both the Google and Microsoft prototypes 
could potentially utilize any number of mobile medical device accessories 
and apps to monitor and interpret the wearer’s bio-data, achieving the exact 
functional definition of the “mobile platform,” yet both fall outside of the 
limited handheld platforms typically used as smartphones. Even more, Ford 
Motor Company is developing integrated sensors embedded in the steering 
wheel and driver seatbelt of its new vehicles to monitor the driver’s facial 
 
 184. THOMPSON, supra note 118, at 9. 
 185. Id. at 26. 
 186. See Wireless Telecommunications Bureau, FED. COMM’N COMM., http://www.fcc.gov/ 
what-we-do (last visited Nov. 16, 2013). 
 187. James Rivington, Google Glass: What You Need to Know, TECH RADAR, 
http://www.techradar.com/us/news/video/project-glass-what-you-need-to-know-1078114 
(last updated Feb. 15, 2012). 
 188. Charles Arthur, Microsoft Gets Patent on Augmented Reality Glasses as “AR Wars” 
Start, THE GUARDIAN (Nov. 27, 2012), http://www.guardian.co.uk/technology/2012/nov/27/ 
microsoft-augmented-reality-glass-google-apple. 
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temperature and compare it with the ambient temperature in the cabin, as 
well as conductive heart rate monitors and piezoelectric sensors in the lap 
belt to detect changes in heart rate and breathing, respectively.189 These 
sensors are designed to interpret the vital driver data and alert the driver 
when physiological and biological signals indicate driver distraction.190 
To extrapolate the “handheld” dilemma, under the proposed Final 
Guidance definitions, would an app running on Google’s “Project Glass” 
that is designed to detect cataracts fall outside the definition of a “mobile 
medical app” because it does not technically operate on a “mobile 
platform”? What about the Ford car that monitors driver vitals? It is 
(equivocally) a mobile medical device, after all. While the steering wheel is 
“handheld” to an extent, the lap belt is akin to the “wearable computer” 
glasses. Yet all these are platforms upon which mobile medical apps could 
be executed. Substitute “portable” or “wireless” for “handheld,” and the 
problem might be solved. This may be yet another complication that will 
result in more FDA guidance down the road, indicating that this Final 
Guidance is not so final after all. In fact, the FDA quite clearly dodged 
offering any guidance whatsoever concerning app software that “performs 
patient-specific analysis to aid or support clinical decision-making” and 
“accessories to medical devices” and apps.191 
Not only should the FDA encourage or require developers and 
manufacturers to integrate self-monitoring features for apps and devices, 
but it should also require mobile app manufacturers to program their apps 
to report adverse event data compatible with the FDA’s own adverse event 
reporting system, the Sentinel Initiative.192 Apps designed for smartphones 
and tablets already collect many different types of information as a 
background process to be sent back to the app developer, tracking each 
and every “click” or action within the app, when the app is in use, the 
location of the user during use, and the duration of that use.193 Some apps 
even collect data when they (or the phone itself) are not in use.194 So an 
FDA requirement for mobile app manufacturers to compile that data and 
pass it along to the Sentinel Initiative system is not particularly burdensome. 
 
 189. Doug Newcomb, How Ford Calculates Driver Workload to Dial Back Distractions, 
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 191. FINAL GUIDANCE, supra note 25, at 12. 
 192. See FDA’s Sentinel Initiative – Background, FOOD & DRUG ADMIN., http://www.fda. 
gov/Safety/FDAsSentinelInitiative/ucm149340.htm (last updated Jan. 9, 2010). 
 193. See Abby Abazorius, CSAIL Research Examines How Smartphone Apps Track Users, 
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Since the system is already in place, this would not require an unreasonable 
resource allocation. 
All things considered, the FDA faces numerous financial and logistical 
hurdles in its office with respect to processing applications and overseeing 
compliance and safety. For example, the FDA must prepare itself for the 
potential deluge of adverse event reports under its Medical Device Reporting 
(MDR) structure195 as the number of mobile medical app manufacturers is 
expected to increase exponentially now that the final guidance has been 
issued.196 Because the rate of innovation vastly surpasses the timeline and 
barriers accompanied by current regulation and oversight structures,197 one 
solution proposed by the U.S. House of Representatives would create a new 
FDA “Office of Mobile Health” and other offices in a bill called the Health 
Information Marketplace Technologies Act (HIMTA).198 Creating an Office 
of Mobile Health would establish a branch of the agency sensitive to the 
dynamic changes in mobile medical technology that could provide a quicker 
turnaround scheme for premarket approval that is not time and cost 
prohibitive. Granted, the solution to every problem in government may not 
always be to create a new office, committee, or position, but given the 
overall benefits to the health care profession that mobile medical device 
technology — including the economic savings of low-cost devices — a new 
office might be worth the extra funding. 
VI.  CONCLUSION 
As technology advances and becomes even more widely used, the 
learning curve for mobilechondriacs and health care providers will flatten 
out, resulting in a shift from responsive care to individualized preventative 
care and an improvement in patient outcomes. Because mobile medical 
apps could be much cheaper to produce and to purchase than stand-alone 
devices, the cost savings of “going mobile” would be passed down to the 
health care consumer, consistent with the goals of the Affordable Care Act 
to improve patient outcomes and lower the cost of health care in our nation. 
Nonetheless, the risks associated with mobile medical devices remain, and 
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despite possible liability apportionment in common law remedies, the FDA 
must balance its new mobile medical app regulations to simultaneously 
protect the consumer and also encourage innovation. Even so, the mobile 
medical app industry will provide the most substantial oversight where FDA’s 
budget and infrastructure are lacking. With more resources, and the right 
political backing, creating the Office of Mobile Health could shift some of 
that burden away from the manufacturers as regulation may require. 
Ultimately, whether or not the FDA’s final guidance addresses these 
enumerated concerns, the bulk of the Final Guidance places a necessary 
level of responsibility on the mobile medical app manufacturer. 
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